Quarterly ResultAug 5, 2026, 07:05 AM
AC Immune H1 2026 Contract Revenue CHF 16.2M; Loss CHF 12.9M
AI Summary
AC Immune reported a significant increase in contract revenue to CHF 16.2 million for the first half of 2026, up from CHF 2.3 million in the prior comparable period. The company also substantially reduced its loss for the period to CHF 12.9 million, down from CHF 40.2 million in H1 2025. Key drivers included milestone payments from Takeda and an upfront payment from Eli Lilly following an amended collaboration agreement, alongside a new research grant. The company provided positive updates on its clinical-stage programs, including interim results for ACI-24 in the ABATE trial and progress in the VacSYn trial for ACI-7104.
Key Highlights
- Contract revenue increased to CHF 16.2 million for H1 2026, up from CHF 2.3 million in H1 2025.
- Loss for the period significantly reduced to CHF 12.9 million in H1 2026, compared to CHF 40.2 million in H1 2025.
- Operating loss decreased to CHF 13.6 million in H1 2026, from CHF 38.8 million in H1 2025.
- Cash and cash equivalents stood at CHF 27.8 million as of June 30, 2026.
- Short-term financial assets were CHF 47.6 million as of June 30, 2026.
- Received a $12.0 million (CHF 9.5 million) milestone payment from Takeda for Cohort AD4 in the ABATE trial.
- Received CHF 11.0 million from Eli Lilly, including a CHF 10.0 million upfront payment, following an amended agreement.
- Secured a $4 million (CHF 3.2 million) research grant from The Vijay and Marie Goradia Charitable Foundation.
Price Impact
More from ACIU